* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10678706.str



chain nodes :
10 11 12 13 14 15 16
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
9-10 10-11 11-12 12-13 13-14 13-16 14-15
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds :
2-7 3-9 7-8 8-9 11-12 12-13 13-16 14-15
exact bonds :
9-10 10-11 13-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 12:45:00 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 10440 TO ITERATE

 19.2% PROCESSED 2000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 202677 TO 214923
PROJECTED ANSWERS: 142471 TO 152771

L2 50 SEA SSS SAM L1

=>
Uploading C:\Program Files\Stnexp\Queries\106787061.str



chain nodes :
10 11 12 13 14 15 16 19 20
ring nodes :
1 2 3 4 5 6 7 8 9

chain bonds :
9-10 10-11 11-12 12-13 13-14 13-16 14-15 14-19 19-20
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds :
2-7 3-9 7-8 8-9 11-12 12-13 13-16 14-15 19-20
exact bonds :
9-10 10-11 13-14 14-19
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:Cy,Ak,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 19:CLASS 20:CLASS

L3 STRUCTURE UPLOADED

=> d
L3 HAS NO ANSWERS
L3 STR



G1 Cy,Ak,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l3
SAMPLE SEARCH INITIATED 12:51:00 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 10157 TO ITERATE

19.7% PROCESSED 2000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

```
PROJECTED ITERATIONS:        197101 TO   209179
PROJECTED ANSWERS:           110431 TO   119523

L4            50 SEA SSS SAM L3

=> s l3 full
FULL SEARCH INITIATED 12:51:12 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   203100 TO ITERATE

 98.3% PROCESSED   199605 ITERATIONS                          113756 ANSWERS

100.0% PROCESSED   203100 ITERATIONS                          116380 ANSWERS
SEARCH TIME: 00.00.19

L5        116380 SEA SSS FUL L3

=> s l5 and pseudodipeptide
              0 PSEUDODIPEPTIDE
L6            0 L5 AND PSEUDODIPEPTIDE

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   177.42     177.90

FILE 'CAPLUS' ENTERED AT 12:52:52 ON 14 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 14 Mar 2006  VOL 144 ISS 12
FILE LAST UPDATED: 13 Mar 2006  (20060313/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l5
L7         43767 L5

=> s l7 AND PSEUDODIPEPTIDE
            162 PSEUDODIPEPTIDE
            197 PSEUDODIPEPTIDES
            291 PSEUDODIPEPTIDE
                  (PSEUDODIPEPTIDE OR PSEUDODIPEPTIDES)
L8            6 L7 AND PSEUDODIPEPTIDE
```

10678706 2/28/06

=> D IBIB ABS HITSTR TOT

L8 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:184245 CAPLUS
DOCUMENT NUMBER: 142:411637
TITLE: Facile degradative lactonization of Gln-Arg and Gln-Phe hydroxyethylene dipeptide derivatives
AUTHOR(S): Haug, B. E.; Brewer, M.; Rich, D. H.
CORPORATE SOURCE: School of Pharmacy and Department of Chemistry, University of Wisconsin-Madison, WI, USA
SOURCE: Journal of Peptide Research (2005), 65(1), 77-83
CODEN: JPERFA; ISSN: 1397-002X
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We have found that hydroxyethylene (HE) dipeptide analogs of Gln-Arg and Gln-Phe are unusually susceptible to acid catalyzed lactonization. The synthesis of substrate-based transition state analog inhibitors of botulinum neurotoxin metalloprotease that contain the Gln-Arg or the Gln-Phe HE units is complicated by this facile degradative lactonization.

IT **850263-98-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(solid phase peptide synthesis of transition state analog inhibitors of botulinum neurotoxin metalloprotease)

RN 850263-98-8 CAPLUS

CN L-Lysinamide, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-seryl-(αR)-α-[(2R,3S)-3-amino-2,6-dihydroxyhexyl]benzenepropanoyl-L-α-glutamyl-L-threonyl-L-seryl-L-alanyl-L-alanyl-L-lysyl-L-leucyl-L-lysyl-L-arginyl-L-lysyl-L-tyrosyl-L-tryptophyl-L-tryptophyl-L-lysyl-L-asparaginyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L8 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B





PAGE 1-C

L8 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



PAGE 2-C



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:702118 CAPLUS
DOCUMENT NUMBER: 141:218943
TITLE: Compositions and methods for enhancing apoptosis using BIR domain-binding oligopeptides to release melanoma inhibitor of apoptosis protein from caspase
INVENTOR(S): Fairbrother, Wayne J.; Deshayes, Kurt; Fischer, Saloumeh; Flygare, John A.; Franklin, Matthew C.; Vucic, Domagoj
PATENT ASSIGNEE(S): Genentech, Inc., USA
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004072641	A1	20040826	WO 2003-US3799	20030207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2514316	AA	20040826	CA 2003-2514316	20030207
AU 2003216203	A1	20040906	AU 2003-216203	20030207
EP 1590666	A1	20051102	EP 2003-815888	20030207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			WO 2003-US3799 W	20030207
OTHER SOURCE(S):	MARPAT 141:218943			

AB The present invention is directed to compns. of matter useful for the enhancement of apoptosis in mammals and to methods of using those compns. of matter for the same. BDB (BIR domain-binding) oligopeptides that specifically bind to ML-IAP (melanoma inhibitor of apoptosis) and release the inhibitory effect ML-IAP has on caspase activity are claimed. Apoptosis in cancer cells is increased by administering the oligopeptide.

IT **214556-79-3D**, fusion proteins with peptides
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(apoptosis induction by; enhancing apoptosis using BIR domain-binding oligopeptides to release melanoma inhibitor of apoptosis protein from caspase)

RN 214556-79-3 CAPLUS

CN L-Lysinamide, L-arginyl-L-glutaminyl-L-isoleucyl-L-lysyl-L-isoleucyl-L-tryptophyl-L-phenylalanyl-L-glutaminyl-L-asparaginyl-L-arginyl-L-arginyl-L-methionyl-L-lysyl-L-tryptophyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L8 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



L8 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



L8 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:578804 CAPLUS
DOCUMENT NUMBER: 132:152110
TITLE: Totally stereocontrolled synthetic routes for (E)-alkene dipeptide isosteres
AUTHOR(S): Fujii, N.; Ibuka, T.; Mimura, N.; Tamamura, H.; Otaka, A.; Ohno, H.; Aoyama, H.; Okano, K.; Hirohashi, M.
CORPORATE SOURCE: Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, 606-8501, Japan
SOURCE: Peptide Science: Present and Future, Proceedings of the International Peptide Symposium, 1st, Kyoto, Nov. 30-Dec. 5, 1997 (1999), Meeting Date 1997, 502-503. Editor(s): Shimonishi, Yasutsugu. Kluwer: Dordrecht, Neth.
CODEN: 68BYA5
DOCUMENT TYPE: Conference
LANGUAGE: English
GI



I

AB A report from a symposium on totally stereocontrolled synthetic routes for the preparation of (E)-alkene dipeptide isosteres starting from aziridinylenoates. The practical application of the diastereoconvergent process to derivatizations of potential peptide-lead drugs involving Ras-Farnesyl transferase inhibitor and bombesin/GRP antagonist was examined Thus, peptide analogs I (R = iso-Pr, PhCH2) and (E)-alkene bombesin isostere (EABI-1) were prepared and their biol. activities tested.

IT 178035-27-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(stereoselective synthesis and biol. activity of peptide analogs containing alkene dipeptide isosteres)

RN 178035-27-3 CAPLUS
CN 1-7-Litorin (peptide), 1-D-phenylalanine-7-[N-[(4R)-4-(aminocarbonyl)-6-methyl-(1S)-1-(2-methylpropyl)-(2E)-2-heptenyl]-L-histidinamide]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L8 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:758608 CAPLUS
DOCUMENT NUMBER: 123:170184
TITLE: New pseudo-dipeptide derivatives, their preparation, and their use as gastrin antagonists.
INVENTOR(S): Martinez, Jean; Riquet, William; Bigg, Dennis; Halazy, Serge
PATENT ASSIGNEE(S): Fabre Pierre Medicament, Fr.
SOURCE: Fr. Demande, 36 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2697843	A1	19940513	FR 1992-13542	19921110
WO 9411390	A1	19940526	WO 1993-FR1099	19931109

W: CA, JP, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
PRIORITY APPLN. INFO.: FR 1992-13542 A 19921110
OTHER SOURCE(S): MARPAT 123:170184
GI



I



II

AB Title compds. I [Z = (un)substituted Ph, PhCH2, indanyl, (poly)cycloalkyl, indolylalkyl, naphthyl, naphthylmethyl, PhOCH2, naphthoxymethyl; R1 = (CH2)nCO2H; n = 1-5; R2 = alkyl; X = NH or CO; Y = CO or NH; X ≠ Y; Z' = H, Me; Z'' = H, CO2R3, NHCO2R3; if Y = NH, Z'' ≠ NHCOR3; if Y = CO, Z'' ≠ COR3; R3 = (un)substituted alkyl, (poly)cycloalkyl, Ph] and salts are claimed and prepared (14 examples). I are gastrin and CCK receptor antagonists, and are claimed useful for treating ulcers, Zollinger-Ellison syndrome, and reflux-induced esophagitis. For example, amidation of tryptamine with Boc-D-Nle-OSu [Boc = tert-BuOCO, Su = N-succinimidyl] in DMF gave 79% Boc-D-Nle-NHCH2CH2R [R = 3-indolyl]. This was deprotected with CF3CO2H and coupled with Z-D-Glu(OCH2Ph)-ONp [Z =

L8 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
PhCH2OCO, Np = C6H4NO2-p] in DMF in the presence of HOBT and DIEA to give 94% Z-D-Glu(OCH2Ph)-D-Nle-NHCH2CH2R. Hydrogenolysis of the latter compd. and coupling with 3,4-Cl2C6H3CO2Su in DMF in the presence of DIEA gave title compd. D,D-II. In the EtOH-induced ulcer test in mice, this compd. gave 80% inhibition at 25 mg/kg p.o.
IT 166945-35-3P 166945-37-5P 166945-38-6P
166945-39-7P 166945-40-0P 166945-41-1P
166945-42-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pseudo-dipeptides as gastrin and CCK antagonists)
RN 166945-35-3 CAPLUS
CN D-Norleucinamide, N-[(phenylmethoxy)carbonyl]-L-α-glutamyl-N-[2-(1H-indol-3-yl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 166945-37-5 CAPLUS
CN Carbamic acid, [1-[[[2-(1H-indol-3-yl)ethyl]amino]carbonyl]pentyl]-, 1,1-dimethylethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 166945-38-6 CAPLUS
CN L-Norleucinamide, N-[(phenylmethoxy)carbonyl]-L-α-glutamyl-N-[2-(1H-indol-3-yl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L8 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 166945-39-7 CAPLUS
CN L-Norleucinamide, N-[(phenylmethoxy)carbonyl]-D-α-glutamyl-N-[2-(1H-indol-3-yl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 166945-40-0 CAPLUS
CN Carbamic acid, [1-[[[2-(1H-indol-3-yl)ethyl]amino]carbonyl]pentyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 166945-41-1 CAPLUS
CN D-Norleucinamide, N-[(phenylmethoxy)carbonyl]-D-α-glutamyl-N-[2-(1H-indol-3-yl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L8 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 166945-42-2 CAPLUS
CN D-Norleucinamide, D-α-glutamyl-N-[2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 166945-19-3P 166945-20-6P 166945-21-7P
166945-22-8P 166945-23-9P 166945-24-0P
166945-25-1P 166945-26-2P 166945-27-3P
166945-28-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pseudo-dipeptides as gastrin and CCK antagonists)
RN 166945-19-3 CAPLUS
CN L-Norleucinamide, N-(3,4-dichlorobenzoyl)-L-α-glutamyl-N-[2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 166945-20-6 CAPLUS
CN L-Norleucinamide, N-(3,4-dichlorobenzoyl)-D-α-glutamyl-N-[2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.



RN 166945-21-7 CAPLUS
CN D-Norleucinamide, N-(3,4-dichlorobenzoyl)-D-α-glutamyl-N-[2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 166945-22-8 CAPLUS
CN D-Norleucinamide, N-(3,4-dichlorobenzoyl)-L-α-glutamyl-N-[2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 166945-23-9 CAPLUS
CN D-Norleucinamide, N-[(3,4-dichlorophenyl)acetyl]-D-α-glutamyl-N-[2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L8 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 166945-27-3 CAPLUS
CN D-Norleucinamide, N-(1-naphthalenylcarbonyl)-D-α-glutamyl-N-[2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 166945-28-4 CAPLUS
CN D-Norleucinamide, N-(2-naphthalenylcarbonyl)-D-α-glutamyl-N-[2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 166945-44-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of pseudo-dipeptides as gastrin and CCK antagonists)
RN 166945-44-4 CAPLUS
CN Hexanamide, 2-amino-N-[2-(1H-indol-3-yl)ethyl]-, (S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 166945-43-3
CMF C16 H23 N3 O

Absolute stereochemistry.

L8 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 166945-24-0 CAPLUS
CN D-Norleucinamide, N-[(3,4-dichlorophenoxy)acetyl]-D-α-glutamyl-N-[2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 166945-25-1 CAPLUS
CN D-Norleucinamide, N-(2-naphthalenylacetyl)-D-α-glutamyl-N-[2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 166945-26-2 CAPLUS
CN D-Norleucinamide, N-(1-naphthalenylacetyl)-D-α-glutamyl-N-[2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L8 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L8 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1992:449229 CAPLUS
DOCUMENT NUMBER: 117:49229
TITLE: Ketomethylene analogs of phosphoryl dipeptides related to phosphoramidon: synthesis and inhibition of proteases
AUTHOR(S): Gomez-Monterrey, Isabel; Gonzalez Muniz, Rosario; Perez-Martin, Concepcion; Lopez de Ceballos, Maria; Del Rio, Joaquin; Garcia-Lopez, M. Teresa
CORPORATE SOURCE: Med. Chem. Inst., Madrid, 28006, Spain
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1992), 325(5), 261-5
CODEN: ARPMAS; ISSN: 0365-6233
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Non-rhamnose-containing phosphoramidon analogs H2O3P-Leu-CH2CHRCO2Me (I; R = Ph, 3-indolyl), in which the amide bond was replaced by the isosteric ketomethylene group, were prepared to stabilize these compds. to peptidase degradation The key step in this synthesis was suitable alkylation of 4-ketodiester Z-Leu-CH2CH(CO2Me)2 (Z = PhCH2O2C), prepared from Z-Leu-CH2Cl and CH2(CO2Me)2. The ketomethylene dipeptide derivs. I are good inhibitors of thermolysin, angiotensin-converting enzyme (ACE), and especially enkephalinase.
IT 36357-77-4DP, Phosphoramidon, non-rhamnose-containing ketomethylene analogs
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as protease inhibitors)
RN 36357-77-4 CAPLUS
CN L-Tryptophan, N-[[(6-deoxy-α-L-mannopyranosyl)oxy]hydroxyphosphinyl]-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L8 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1981:192668 CAPLUS
DOCUMENT NUMBER: 94:192668
TITLE: Pseudodipeptides: synthesis and incorporation within analogs of LH-RH
AUTHOR(S): Spatola, A. F.; Bettag, A. L.; Fok, K. F.; Saneii, H.; Yankeelov, J. A., Jr.
CORPORATE SOURCE: Dep. Chem. Biochem., Univ. Louisville, Louisville, KY, 40208, USA
SOURCE: Pept., Struct. Biol. Funct., Proc. Am. Pept. Symp., 6th (1979), 273-6. Editor(s): Gross, Erhard; Meienhofer, Johannes. Pierce Chem. Co.: Rockford, Ill.
CODEN: 44LVAU
DOCUMENT TYPE: Conference
LANGUAGE: English
AB Pseudodipeptides H-Gly-ΨLeu-OH (Ψ = CH2S replacement for CONH), H-Gly-ΨIle-OH, H-Ser-ΨLeu-OH, H-D-Ser-ΨLeu-OH, and Me3CO2-X-ΨGly-OH [X = Phe, Tyr(CH2Ph), Pro] were prepared and Gly-ΨLeu was incorporated into LH-releasing hormone (LH-RH) analogs [Gly-ΨLeu6,7]-LH-RH and [D-pyroGlu1, D-Phe2, D-Trp3, Gly-ΨLeu6,7]-LH-RH by solid-phase peptide synthesis. Biol. activities of these LH-RH analogs were determined
IT 53422-04-1 68059-94-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(biol. activity of)
RN 53422-04-1 CAPLUS
CN Luteinizing hormone-releasing factor (swine), 2-D-phenylalanine- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L8 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B



=NH

RN 68059-94-9 CAPLUS
CN Glycinamide, 5-oxo-D-prolyl-D-phenylalanyl-D-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L8 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



IT 76509-48-3P 76509-51-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and biol. activity of)
RN 76509-48-3 CAPLUS
CN Luteinizing hormone-releasing factor (swine), 6-[2-[(2-aminoethyl)thio]-4-methylpentanoic acid]-7-de-L-leucine-, (S)- (9CI) (CA INDEX NAME)

PAGE 1-A



L8 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 76509-51-8 CAPLUS
CN Glycinamide, N2-[4-methyl-1-oxo-2-[[2-[[N-[N-[N-[N-(5-oxo-D-prolyl)-D-phenylalanyl]-D-tryptophyl]-L-seryl]-L-tyrosyl]amino]ethyl]thio]pentyl]-L-arginyl-L-prolyl-, (S)- (9CI) (CA INDEX NAME)

PAGE 1-A



L8 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



10678706 2/28/06

=> LOGOFF
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	35.37	213.27

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.50	-4.50

STN INTERNATIONAL LOGOFF AT 12:56:38 ON 14 MAR 2006